97.95

2.40% 2.30

After Hours: 97.95

Mirum Pharmaceuticals Inc (MIRM)

Overview News Price History Option Chain Financials Why MIRM Down? Discussions Forecast

Mirum Pharmaceuticals Inc stock is traded at $97.95, with a volume of 697.19K. It is up +2.40% in the last 24 hours and up +13.50% over the past month. Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.

Previous Close:

$95.65

Open:

$98.245

24h Volume:

697.19K

Relative Volume:

0.81

Market Cap:

$5.91B

Revenue:

$521.31M

Net Income/Loss:

$-23.36M

P/E Ratio:

-204.87

EPS:

-0.4781

Net Cash Flow:

$54.87M

1W Performance:

+3.52%

1M Performance:

+13.50%

6M Performance:

+34.45%

1Y Performance:

+149.11%

1-Day Range:

$96.21

$98.63

1-Week Range:

$92.37

$98.63

52-Week Range:

$36.88

$109.28

Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile

Name

Mirum Pharmaceuticals Inc

Sector

Healthcare (1111)

Industry

Biotechnology (624)

Phone

650-667-4085

Address

989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY

Employee

372

Twitter

@mirumpharma

Next Earnings Date

2024-11-04

Latest SEC Filings

MIRM's Discussions on Twitter

Compare MIRM vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MIRM Mirum Pharmaceuticals Inc	97.95	5.77B	521.31M	-23.36M	54.87M	-0.4781
VRTX Vertex Pharmaceuticals Inc	443.92	109.85B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	775.53	80.38B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	785.07	47.60B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	327.25	42.63B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	312.19	33.72B	5.36B	287.73M	924.18M	2.5229

Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-18-26	Initiated	RBC Capital Mkts	Outperform
Sep-24-25	Initiated	TD Cowen	Buy
Aug-11-25	Resumed	Stifel	Buy
May-19-25	Resumed	H.C. Wainwright	Buy
Apr-17-24	Initiated	Stifel	Buy
Dec-18-23	Reiterated	H.C. Wainwright	Buy
Nov-20-23	Resumed	JP Morgan	Overweight
Nov-13-23	Initiated	Morgan Stanley	Overweight
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-17-23	Resumed	Evercore ISI	Outperform
Sep-20-23	Initiated	JMP Securities	Mkt Outperform
Sep-01-22	Initiated	Citigroup	Buy
Sep-20-21	Initiated	JP Morgan	Overweight
Aug-07-20	Upgrade	Raymond James	Outperform → Strong Buy
Aug-03-20	Initiated	H.C. Wainwright	Buy
Jul-31-20	Initiated	Piper Sandler	Overweight
Jun-25-20	Initiated	Robert W. Baird	Outperform
Aug-12-19	Initiated	Citigroup	Buy
Aug-12-19	Initiated	Evercore ISI	Outperform
Aug-12-19	Initiated	Guggenheim	Buy
Aug-12-19	Initiated	ROTH Capital	Buy
Aug-12-19	Initiated	Raymond James	Outperform

View All

Mirum Pharmaceuticals Inc Stock (MIRM) Latest News

Apr 07, 2026

Primary Sclerosing Cholangitis Market is expected to Hit US$ - openPR.com

Apr 07, 2026

18,710 Shares in Mirum Pharmaceuticals, Inc. $MIRM Purchased by SG Americas Securities LLC - MarketBeat

Apr 07, 2026

Apr 06, 2026